160 related articles for article (PubMed ID: 38446397)
1. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
Rheumatol Ther; 2024 Jun; 11(3):817-828. PubMed ID: 38446397
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
Warren RB; McInnes IB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; Mease PJ
Rheumatol Ther; 2024 Jun; 11(3):829-839. PubMed ID: 38488975
[TBL] [Abstract][Full Text] [Related]
3. Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies.
Gossec L; Orbai AM; de Wit M; Coates LC; Ogdie A; Ink B; Coarse J; Lambert J; Taieb V; Gladman DD
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38754125
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden.
Sigurdardottir V; Engstrom A; Berling P; Olofsson T; Oldsberg L; Sadler S; Parra-Padilla D; Melis L; Willems D
J Med Econ; 2023; 26(1):1190-1200. PubMed ID: 37712618
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison.
Mease P; Choy E; Nash P; Kalyvas C; Hunger M; Pricop L; Gandhi KK; Jugl SM; Thom H
Eur J Rheumatol; 2019 Jul; 6(3):113-121. PubMed ID: 31364979
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies.
Orbai AM; Husni ME; Gladman DD; Leung YY; Siebert S; Tillett W; Vis M; Chambenoit O; Meng X; Mease PJ
Rheumatol Ther; 2021 Sep; 8(3):1223-1240. PubMed ID: 34218429
[TBL] [Abstract][Full Text] [Related]
7. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
Mease PJ; Gladman DD; Merola JF; Nash P; Grieve S; Laliman-Khara V; Willems D; Taieb V; Prickett AR; Coates LC
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38218744
[TBL] [Abstract][Full Text] [Related]
10. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
Xu Y; Li Y; Dong M; Gao Z; Chen X; Liu H; Shen M
Rheumatology (Oxford); 2020 Dec; 59(12):3657-3665. PubMed ID: 33038239
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Carter K; Stakias V; Lippe R; Drogaris L; Soliman AM; Chen MM; Padilla B; Kivitz A
Rheumatol Ther; 2024 Jun; 11(3):633-648. PubMed ID: 38498139
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model-Based Meta-Analysis of American College of Rheumatology Response Criteria.
Maloney A; Dua P; Ahmed GF
Clin Pharmacol Ther; 2024 May; 115(5):1007-1014. PubMed ID: 38073049
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
Ogdie A; Merola JF; Mease PJ; Ritchlin CT; Scher JU; Lafferty KP; Chan D; Chakravarty SD; Langholff W; Wang Y; Choi O; Krol Y; Gottlieb AB
BMC Rheumatol; 2024 May; 8(1):20. PubMed ID: 38773563
[TBL] [Abstract][Full Text] [Related]
14. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ritchlin CT; Coates LC; McInnes IB; Mease PJ; Merola JF; Tanaka Y; Asahina A; Gossec L; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Landewé RB
Ann Rheum Dis; 2023 Nov; 82(11):1404-1414. PubMed ID: 37696588
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.
Kivitz AJ; Kremer JM; Legerton CW; Pricop L; Singhal A
Rheumatol Ther; 2024 Jun; 11(3):675-689. PubMed ID: 38625671
[TBL] [Abstract][Full Text] [Related]
16. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
Nash P; Mease PJ; McInnes IB; Rahman P; Ritchlin CT; Blanco R; Dokoupilova E; Andersson M; Kajekar R; Mpofu S; Pricop L;
Arthritis Res Ther; 2018 Mar; 20(1):47. PubMed ID: 29544534
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.
McInnes IB; Mease PJ; Kivitz AJ; Nash P; Rahman P; Rech J; Conaghan PG; Kirkham B; Navarra S; Belsare AD; Delicha EM; Pricop L
Lancet Rheumatol; 2020 Apr; 2(4):e227-e235. PubMed ID: 38268157
[TBL] [Abstract][Full Text] [Related]
20. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
Coates LC; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Orbai AM; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Merola JF
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38388171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
